Skip to main content
Healthcare

STAT+: Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial

STAT+: Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial

Feed excerpt — reported by STAT News

Sellas' experimental blood cancer immunotherapy reduced the risk of death in clinical trial.

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →

Original Source

This article was syndicated from STAT News. All rights remain with the original publisher.